GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » EPS without NRI

PuraPharm (HKSE:01498) EPS without NRI

: HK$-0.24 (TTM As of Dec. 2023)
View and export this data going back to 2015. Start your Free Trial

PuraPharm's earnings per share without non-recurring items for the six months ended in Dec. 2023 was HK$-0.14. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.24.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for PuraPharm's EPS without NRI or its related term are showing as below:

During the past 10 years, PuraPharm's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 28.90% per year. The lowest was -20.20% per year. And the median was 4.35% per year.

HKSE:01498's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 11.4
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

PuraPharm's EPS (Diluted) for the six months ended in Dec. 2023 was HK$-0.17. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.27.

PuraPharm's EPS (Basic) for the six months ended in Dec. 2023 was HK$-0.17. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.27.


PuraPharm EPS without NRI Historical Data

The historical data trend for PuraPharm's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.77 0.11 -0.30 -0.28 -0.24

PuraPharm Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.11 -0.17 -0.10 -0.14

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PuraPharm PE Ratio without NRI Distribution

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where PuraPharm's PE Ratio without NRI falls into.



PuraPharm EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PuraPharm  (HKSE:01498) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


PuraPharm EPS without NRI Related Terms

Thank you for viewing the detailed overview of PuraPharm's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


PuraPharm (HKSE:01498) Business Description

Traded in Other Exchanges
N/A
Address
Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. In addition, the organization is engaged in rendering Chinese medical diagnostic services. The operating segments of the group are China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation and Clinics. It generates maximum revenue from the China CCMG segment mainly engages in the production and sale of CCMG products in China. The group derives revenue from the customers located in Hong Kong, Mainland China and Other countries.

PuraPharm (HKSE:01498) Headlines

No Headlines